Imagine a heart valve like a leaky door that lets blood flow backward. Instead of replacing the whole door through open surgery, this device acts like a custom-fit patch that slides over the leaky part. It uses a smart metal frame that remembers its shape to snap into place and stop the leak without needing a major operation.
Current mitral valve treatments have high failure rates (up to 90%) or require invasive open-heart surgery, leaving millions of heart failure patients without viable options.
A hemi valve called the Mitral Butterfly consisting of a Nitinol frame, a flexible mesh artificial leaflet, and a self-expanding anchorage mechanism.
If you are a cardiac implant manufacturer dealing with high screen failure rates of up to 90% in current transcatheter repairs — this project developed the Mitral Butterfly system that provides a stable, atraumatic seating to treat more patients.
If you are a software provider dealing with imprecise pre-surgical planning — this project developed a digital twin for navigation and implantation that helps doctors iterate the best implant based on patient anatomy.
If you are a clinic dealing with patients who are inoperable for standard open-heart surgery — this project developed a transseptal delivery method for a hemi valve that restores heart function without open-heart surgery.
Based on available project data, specific pricing and cost structures for the device are not provided.
The project focuses on an innovation loop to standardize testing and iterate the implant design using a digital twin, though mass production details are not specified.
Based on available project data, the project utilizes a nitinol-based frame and a secondary self-expanding mechanism, but specific patent or licensing terms are not listed.
The device must address the need for atraumatic implant seating and prevent unphysiological inflow to meet safety standards for heart failure patients.
The project period is from 2023-02-01 to 2025-01-31, suggesting the development phase concludes in early 2025.
The project is led by a single SME, AVVIE GMBH, based in Austria. With a 100% industry ratio and a total EU contribution of EUR 2,499,999, the project is lean and focused on commercialization rather than academic research, lacking university or research institute partners in the consortium.
Contact AVVIE GMBH in Austria
Contact us to explore licensing opportunities for the Mitral Butterfly system.
